Company Description
With trusted scientific insight brought to every program and 35+ years of ensuring quality & control throughout the development process, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast.
Services for drug product span from early phase to late-stage and commercial, and our clinical pharmacology services are focused on early phase, with a full suite of Phase I studies from first-in-human (FIH), single and multiple ascending dose (SAD / MAD) to regulatory and exploratory clinical studies including human ADME, TQT, DDI, and bioavailability studies.
We pioneered the integration of CRDMO services to create Translational Pharmaceutics®—a unique and disruptive platform that integrates drug product manufacturing & clinical testing for better clinical outcomes, reduced costs & timeline acceleration by up to 12 months.
Company Background
We are a trusted CRO/CDMO partner, bringing global experience and capabilities in drug development, manufacturing, and clinical testing to tailor each small molecule and synthetic peptide drug program. Over the past three decades, we’ve worked with small biotech and large pharma customers alike on 3,000+ molecules and 1,300+ clinical programs across all stages of development.
Facilities
- Nottingham, U.K.
- Edinburgh, U.K.
- Miami, U.S.
- Philadelphia, U.S. - Boothwyn
- Philadelphia, U.S. – Garnet Valley
Services and Capabilities
- Formulation development: dosage forms, pre-formulation, solubilization, modified release, pediatrics
- Clinical trial manufacturing: phase I-III clinical supplies, adaptive manufacturing, high-potency APIs
- Clinical pharmacology: first-in-human, BA/BE, human ADME, pharmacy compounding
- Data sciences: data management, programming, statistics/PK, medical writing
- Commercial manufacturing: tech transfer, scale-up, registration, process validation
- Drug development consulting: scientific advice, developability assessment, program design
- Modeling & Simulation: PBPK modeling, FIH predictions, quality-by-design assessments, in-vitro/in-vivo correlations, bioequivalence assessments